{"id":"pirfenidone-8-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Pirfenidone is an antifibrotic agent that suppresses the production of extracellular matrix proteins and pro-inflammatory cytokines, particularly by blocking TGF-β-mediated fibroblast activation. When formulated as a topical gel, it targets dermal fibrosis and inflammatory skin conditions at the site of application, reducing collagen deposition and tissue remodeling.","oneSentence":"Pirfenidone reduces skin fibrosis and inflammation by inhibiting fibroblast proliferation and transforming growth factor-beta (TGF-β) signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:20.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Localized skin fibrosis and scleroderma (topical indication in phase 3)"}]},"trialDetails":[{"nctId":"NCT06909812","phase":"PHASE3","title":"Silicone vs Pirfenidone in the Treatment of Hypertrophic Scars and Keloids","status":"COMPLETED","sponsor":"Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.","startDate":"2015-07-14","conditions":"Scars, Keloids, Hypertrophic Scar","enrollment":40},{"nctId":"NCT02823236","phase":"PHASE3","title":"Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars","status":"UNKNOWN","sponsor":"Centro Dermatológico Dr. Ladislao de la Pascua","startDate":"2016-10-24","conditions":"Keloid","enrollment":102},{"nctId":"NCT02222376","phase":"PHASE3","title":"Effect of Topic Pirfenidone in Diabetic Ulcers","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2013-10","conditions":"Diabetic Foot Ulcers","enrollment":36},{"nctId":"NCT02632877","phase":"PHASE1, PHASE2","title":"Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2014-01","conditions":"Diabetic Foot Ulcer","enrollment":60},{"nctId":"NCT02161952","phase":"PHASE2","title":"Pirfenidone, an Antifibrotic and Antiinflammatory Drug","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2005-05","conditions":"Fibrosis, Hepatitis C Chronic","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["kitoscell"],"phase":"phase_3","status":"active","brandName":"pirfenidone 8% gel","genericName":"pirfenidone 8% gel","companyName":"Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.","companyId":"fundaci-n-nacional-para-la-ense-anza-y-la-investigaci-n-de-la-dermatolog-a-a-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pirfenidone reduces skin fibrosis and inflammation by inhibiting fibroblast proliferation and transforming growth factor-beta (TGF-β) signaling. Used for Localized skin fibrosis and scleroderma (topical indication in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}